[Federal Register Volume 61, Number 158 (Wednesday, August 14, 1996)]
[Notices]
[Pages 42256-42257]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-20703]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[INFO-96-22]


Proposed Data Collections Submitted for Public Comment and 
Recommendations

    In compliance with the requirement of Section 3506(c)(2)(A) of the 
Paperwork Reduction Act of 1995 for opportunity for public comment on 
proposed data collection projects, the Centers for Disease Control and 
Prevention (CDC) will publish periodic summaries of proposed projects. 
To request more information on the proposed projects or to obtain a 
copy of the data collection plans and instruments, call the CDC Reports 
Clearance Officer on (404) 639-7090.
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques for other 
forms of information technology. Send comments to Wilma Johnson, CDC 
Reports Clearance Officer, 1600 Clifton Road, MS-D24, Atlanta, GA 
30333. Written comments should be received within 60 days of this 
notice.

Proposed Projects

    1. Surveillance and Evaluation of Blood Donors Positive for Human 
Immunodeficiency Virus (HIV) Antibody or HIV Antigen (0920-0329). In 
1987, the President directed the Department of Health and Human 
Services (DHHS) to determine the nationwide incidence of, to predict 
the future of, and to determine the extent to which human 
immunodeficiency virus (HIV) is present in various segments of our 
population. In response, CDC formed an epidemiologic team to summarize 
existing information. An extensive review of published and unpublished 
data led to the conclusion that even though there is information 
suggesting a very large number of Americans were infected, there was no 
substitute for carefully and scientifically obtained incidence and 
prevalence data. The need to monitor HIV seroprevalence existed on the 
national and at the state and local levels for public health 
management: targeting and evaluating prevention programs, planning 
future health care needs and determining health policy.
    On a national basis, HIV seroprevalence projects in 1987 consisted 
of monitoring the HIV status of: Civilian applicants for military 
service; blood donors, including follow-up risk factor evaluation in 
seropositives; and Job Corps entrants. HIV prevalence was studied in 
settings of special public health interest including selected colleges 
and prisons, among health care workers in hospital emergency rooms and 
among Native Americans and homeless persons. Other national data 
sources were examined, such as cohort studies of groups at risk, 
including homosexual and bisexual men and IV drug users, providing 
information on knowledge of AIDS and risk behaviors, changes in 
behavior, and incidence of HIV infection.
    In 1987, OMB approved the ``Family of HIV Seroprevalence Surveys'' 
(0920-0232). These surveys included seven seroprevalence surveys which 
involved interaction with individuals (non-blinded surveys). One of 
these surveys was the surveillance and evaluation of blood donors 
positive for Human Immunodeficiency Virus (HIV) Antibody.
    In 1993, OMB again approved for 3 years the surveillance and 
evaluation of blood donors who test positive for Human Immunodeficiency 
Virus (HIV) Antibody and their needle-sharing and sexual partners 
(0920-0329). This request is for an additional 3-year approval. The 
total cost to respondents is estimated at $3,784.

[[Page 42257]]



------------------------------------------------------------------------
                                                        Average         
                                             No. of     burden/   Total 
         Respondents             No. of    responses/  response   burden
                              respondents  respondent     (in      (in  
                                                         hrs.)    hrs.) 
------------------------------------------------------------------------
Blood donors (interviews)...        160            1        1.0      160
Blood donors (refuse                                                    
 interview).................        120            1        0.1       12
                             -------------------------------------------
      Total.................  ...........  ..........  ........      172
                             --------------                             
------------------------------------------------------------------------

    Dated: August 8, 1996.
Wilma G. Johnson,
Acting Associate Director for Policy Planning and Evaluation, Centers 
for Disease Control and Prevention (CDC).
[FR Doc. 96-20703 Filed 8-13-96; 8:45 am]
BILLING CODE 4163-18-P